2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Sunday, December 13, 2026
06:00 p.m. - 08:00 p.m.
MCCNO - Hall F
Access, Representation, Population Health, Technology and Procedures, Assays, Molecular Testing, Treatment Considerations, Combination Therapy, Drug Development, Supportive Care, Therapy Sequence, Biological Therapies, Antibody Therapy, Bispecific Antibody Therapy, (CAR)-T Cell Therapies, Non-Biological Therapies, Pharmacology, Adverse Events, Artificial Intelligence (AI), Machine Learning, Natural Language Processing, Biological Processes, Pathogenesis, Genomics, Multi-Systemic Interactions, Clinical Practice (Health Services and Quality), Clinical Guidelines, Quality of Care, Diseases, Lymphoid Malignancies, Lymphoid Leukemias, Lymphomas, Measurable Residual Disease, CLL, Non-Hodgkin Lymphoma, B Cell Lymphoma, Indolent Lymphoma, Aggressive Lymphoma, Research, Translational Research, Clinical Research, Clinical Trials, Epidemiology, Health Outcomes Research, Health Disparities Research, Real-World Evidence, Registries, Study Population, Human, Adult, Young Adult
PAPER

3892 Efficacy and safety of MRD-guided zanubrutinib-bendamustine combination followed by zanubrutinib monotherapy in treatment-naïve chronic lymphocytic leukemia: A phase III single-arm study

Jiaojiao Zhang II, Shanghai Jiao Tong University School of Medicine, Weiyang Liu, MD2, Jiayi Ren, MD3, Jing Luo4, Jiong Hu, MD5, Li Chen, MD6, Xiangqin Weng7, Jin Wang, MD, PhD8, Jian-Qing Mi9
1 Shanghai Institute of Hematology, State Key Laboratory of Medical Genomics, National Research Center for Translational Medicine at Shanghai, Ruijin Hospital, Shanghai jiao Tong University School of Medicine, Shanghai 200025, China;, shanghai, China, Shanghai Key Laboratory of Gene Editing and Cell-based Immunotherapy for Hematological Diseases, Ruijin Hospital, Shanghai jiao Tong University School of Medicine, Shanghai 200025, China., SHANGHAI, China
2 Shanghai Institute of Hematology, State Key Laboratory of Medical Genomics, National Research Center for Translational Medicine at Shanghai, Ruijin Hospital, Shanghai jiao Tong University School of Medicine, Shanghai 200025, China;, shanghai, China, Shanghai Key Laboratory of Gene Editing and Cell-based Immunotherapy for Hematological Diseases, Ruijin Hospital, Shanghai jiao Tong University School of Medicine, Shanghai 200025, China., SHANGHAI, China
3 Shanghai Institute of Hematology, State Key Laboratory of Medical Genomics, National Research Center for Translational Medicine at Shanghai, Ruijin Hospital, Shanghai jiao Tong University School of Medicine, Shanghai 200025, China;, shanghai, China, Shanghai Key Laboratory of Gene Editing and Cell-based Immunotherapy for Hematological Diseases, Ruijin Hospital, Shanghai jiao Tong University School of Medicine, Shanghai 200025, China., SHANGHAI, China
4 Shanghai Institute of Hematology, State Key Laboratory of Medical Genomics, National Research Center for Translational Medicine at Shanghai, Ruijin Hospital, Shanghai jiao Tong University School of Medicine, Shanghai 200025, China;, shanghai, China
5 Shanghai Institute of Hematology, State Key Laboratory of Medical Genomics, National Research Center for Translational Medicine at Shanghai, Ruijin Hospital, Shanghai jiao Tong University School of Medicine, Shanghai 200025, China;, shanghai, China
6 Shanghai Institute of Hematology, State Key Laboratory of Medical Genomics, National Research Center for Translational Medicine at Shanghai, Ruijin Hospital, Shanghai jiao Tong University School of Medicine, Shanghai 200025, China;, shanghai, China
7 Shanghai Institute of Hematology, State Key Laboratory of Medical Genomics, National Research Center for Translational Medicine at Shanghai, Ruijin Hospital, Shanghai jiao Tong University School of Medicine, Shanghai 200025, China;, shanghai, China
8 Shanghai Institute of Hematology, State Key Laboratory of Medical Genomics, National Research Center for Translational Medicine at Shanghai, Ruijin Hospital, Shanghai jiao Tong University School of Medicine, Shanghai 200025, China;, shanghai, China, Shanghai Key Laboratory of Gene Editing and Cell-based Immunotherapy for Hematological Diseases, Ruijin Hospital, Shanghai jiao Tong University School of Medicine, Shanghai 200025, China., SHANGHAI, China
9 Shanghai Institute of Hematology, State Key Laboratory of Medical Genomics, National Research Center for Translational Medicine at Shanghai, Ruijin Hospital, Shanghai jiao Tong University School of Medicine, Shanghai 200025, China;, shanghai, China, Shanghai Key Laboratory of Gene Editing and Cell-based Immunotherapy for Hematological Diseases, Ruijin Hospital, Shanghai jiao Tong University School of Medicine, Shanghai 200025, China., SHANGHAI, China

Introduction: Zanubrutinib, a next-generation Bruton tyrosine kinase (BTK) inhibitor, has shown efficacy in B-cell malignancies. However, data on zanubrutinib-based combination regimens with minimal residual disease (MRD)-guided treatment decisions in chronic lymphocytic leukemia (CLL) remain limited. This investigator-initiated, single-arm, single-center phase III study evaluated the efficacy and safety of zanubrutinib-bendamustine combination followed by MRD-guided zanubrutinib monotherapy in treatment-naïve (TN) CLL.

Methods: Eligible patients were aged 18–64 years with TN CLL requiring treatment per iwCLL 2018 criteria and ECOG performance status 0–2 (ECOG 3 permitted if CLL-related). Patients received zanubrutinib 160 mg twice daily orally plus bendamustine 90 mg/m² intravenously on days 1–2 for 6 cycles (ZB-stage). After cycle 6 (C6), subsequent therapy was MRD-guided: patients achieving undetectable MRD (uMRD, ≤0.01%) discontinued therapy, while MRD-positive patients continued zanubrutinib monotherapy maintenance. Primary endpoints were overall response rate (ORR) and complete response (CR) rate in the intention-to-treat (ITT) population per iwCLL 2018 criteria. Secondary endpoints included progression-free survival (PFS), overall survival (OS), peripheral blood MRD (PB-MRD) negativity, and safety per NCI-CTCAE v5.0. The study is registered at ClinicalTrials.gov (NCT03336333) and is closed to recruitment.

Results: 35 patients were enrolled (median age 57 years [range, 44–65]; male:female 1.3:1; ECOG 0: 91.4%). By CLL-IPI, 40%, 31.4%, and 28.4% were at low, intermediate, and high risk. Cytogenetics/molecular features: TP53 mutation 5.7%, del(17p) 5.7%, concurrent TP53 mutation/del(17p) 8.6%, del(11q) 8.6%, del(13q) 40%, unmutated IGHV 34.3%. Comorbidities included type 2 diabetes mellitus (14.3%) and hypertension (22.9%). With a median follow-up of 31 months (IQR, 23–37), estimated 46-month OS was 97.1% and 41-month PFS was 97.1%; median OS and PFS were not reached (NR). One death from progressive disease (PD) occurred. For del(17p)/TP53-negative (n=32) vs. -positive (n=3) patients, 41-month PFS was 100% vs. 66.7%. ORR was 100% (35/35). At final evaluation, 16 (45.7%) achieved CR/CRi (15 CR, 1 CRi) and 19 (54.3%) had nPR/PR (15 PR, 4 nPR). Treatment completion rates were 94.3% at C3 and 85.7% at C6; discontinuations/transitions included monotherapy transition after C1 (n=1), gastrointestinal stromal tumor treatment after C3 (n=1), and return to local hospital for monotherapy after C3 (n=3). Dynamic PB-MRD analysis showed uMRD (≤0.01%) rates of 21.2% (7/33) at C3 and 28.1% (9/32) at C6. CR-uMRD rates were 40.0% (6/15) at C3 and 43.8% (7/16) at C6 vs. PR-uMRD rates of 5.0% (1/20) at C3 and 10.5% (2/19) at C6. Regarding safety, neutropenia was the most frequent hematologic toxicity (71.4% ZB-stage vs. 37.0% monotherapy). Grade 3–4 AEs included neutropenia (34.3% vs. 7.4%), thrombocytopenia (8.6% vs. 0%), lung infection (8.6% vs. 11.1%), and hypertension (5.7% vs. 0%; ZB-stage only). Non-hematologic toxicities—rash (37.1% vs. 22.2%) and hemorrhage (37.1% vs. 7.4%)—were more frequent during ZB-stage. The overall safety profile was manageable.

Conclusions: Zanubrutinib-bendamustine combination with MRD-guided zanubrutinib monotherapy demonstrated 100% ORR, favorable PFS and OS, and deepening MRD negativity in TN CLL, including patients with high-risk cytogenetics. The MRD-guided approach enabled treatment discontinuation in uMRD achievers. The safety profile was manageable with predominantly combination-phase hematologic toxicities. Longer follow-up is warranted to assess durability of responses. (NCT03336333)


Jiaojiao Zhang II, Shanghai Jiao Tong University School of Medicine: No relevant conflicts of interest to declare.